The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients
Richir, M. C Ellger, B Teerlink, T Siroen, M. P. C Visser, M Spreeuwenberg, M Girbes, A. R. J van der Hoven, B Van den Berghe, Greet Wilhelm, A. J de Vries, Th. P. G. M van Leeuwen, P. A. M # ×
Academic press ltd- elsevier science ltd
Pharmacological research vol:60 issue:6 pages:519-524
Asymmetric dimethylarginine (ADMA) plays a crucial role in the arginine-nitric oxide pathway. Critically ill patients have elevated levels of ADMA which proved to be a strong and independent risk factor for ICU mortality. The aim of this study was to investigate the effect of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist rosiglitazone on ADMA plasma levels in critically ill patients.